1
|
Wang Y, Bu F, Royer C, Serres S, Larkin
JR, Soto MS, Sibson NR, Salter V, Fritzsche F, Turnquist C, et al:
ASPP2 controls epithelial plasticity and inhibits metastasis
through β-catenin-dependent regulation of ZEB1. Nat Cell Biol.
16:1092–1104. 2014. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Lamora A, Talbot J, Bougras G, Amiaud J,
Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann
MF, et al: Overexpression of smad7 blocks primary tumor growth and
lung metastasis development in osteosarcoma. Clin Cancer Res.
20:5097–5112. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Markou A, Farkona S, Schiza C, Efstathiou
T, Kounelis S, Malamos N, Georgoulias V and Lianidou E: PIK3CA
mutational status in circulating tumor cells can change during
disease recurrence or progression in patients with breast cancer.
Clin Cancer Res. 20:5823–5834. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y,
Zhao L, Qu H, Fan Y and Wu C: Antagonism of miR-21 reverses
epithelial-mesenchymal transition and cancer stem cell phenotype
through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One.
7:e395202012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Mulrane L, McGee SF, Gallagher WM and
O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res.
73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lowery AJ, Miller N, McNeill RE and Kerin
MJ: MicroRNAs as prognostic indicators and therapeutic targets:
Potential effect on breast cancer management. Clin Cancer Res.
14:360–365. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Geng SQ, Alexandrou AT and Li JJ: Breast
cancer stem cells: Multiple capacities in tumor metastasis. Cancer
Lett. 349:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Hardy KM, Booth BW, Hendrix MJ, Salomon DS
and Strizzi L: ErbB/EGF signaling and EMT in mammary development
and breast cancer. J Mammary Gland Biol Neoplasia. 15:191–199.
2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Javelaud D, Alexaki VI, Dennler S,
Mohammad KS, Guise TA and Mauviel A: TGF-β/SMAD/GLI2 signaling axis
in cancer progression and metastasis. Cancer Res. 71:5606–5610.
2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Brand TM, Iida M, Luthar N, Starr MM,
Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in
cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Boudot A, Kerdivel G, Lecomte S, Flouriot
G, Desille M, Godey F, Leveque J, Tas P, Le Dréan Y and Pakdel F:
COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF
signaling and stimulates breast cancer cell migration. BMC Cancer.
14:4072014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Foley J, Nickerson NK, Nam S, Allen KT,
Gilmore JL, Nephew KP and Riese DJ II: EGFR signaling in breast
cancer: Bad to the bone. Semin Cell Dev Biol. 21:951–960. 2010.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Kolch W and Pitt A: Functional proteomics
to dissect tyrosine kinase signalling pathways in cancer. Nat Rev
Cancer. 10:618–629. 2010. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Wagner JP, Wolf-Yadlin A, Sevecka M,
Grenier JK, Root DE, Lauffenburger DA and MacBeath G: Receptor
tyrosine kinases fall into distinct classes based on their inferred
signaling networks. Sci Signal. 6:ra582013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ouyang H, Gore J, Deitz S and Korc M:
microRNA-10b enhances pancreatic cancer cell invasion by
suppressing TIP30 expression and promoting EGF and TGF-β actions.
Oncogene. 33:4664–4674. 2014. View Article : Google Scholar :
|
16
|
Javelaud D, Alexaki VI and Dennler S,
Javelaud D, Alexaki VI and Dennler S: TGF-β/SMAD/GLI2 signaling
axis in cancer progression and metastasis. Cancer Res.
71:5606–5610. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Moses H and Barcellos-Hoff MH: TGF-beta
biology in mammary development and breast cancer. Cold Spring Harb
Perspect Biol. 3:a0032772011. View Article : Google Scholar
|
18
|
Drabsch Y and ten Dijke P: TGF-β signaling
in breast cancer cell invasion and bone metastasis. J Mammary Gland
Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Connolly EC, Freimuth J and Akhurst RJ:
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci.
8:964–978. 2012. View Article : Google Scholar
|
20
|
Kang JS, Liu C and Derynck R: New
regulatory mechanisms of TGF-beta receptor function. Trends Cell
Biol. 19:385–394. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wilczynska A and Bushell M: The complexity
of miRNA-mediated repression. Cell Death Differ. 22:22–33. 2015.
View Article : Google Scholar
|
22
|
Yang F, Zhang W, Shen Y and Guan X:
Identification of dysregulated microRNAs in triple-negative breast
cancer (Review). Int J Oncol. 46:927–932. 2015.PubMed/NCBI
|
23
|
Farazi TA, Horlings HM, Ten Hoeve JJ,
Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F,
van Kouwenhove M, et al: MicroRNA sequence and expression analysis
in breast tumors by deep sequencing. Cancer Res. 71:4443–4453.
2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang K, Zhang Y, Liu C, Xiong Y and Zhang
J: MicroRNAs in the diagnosis and prognosis of breast cancer and
their therapeutic potential (Review). Int J Oncol. 45:950–958.
2014.PubMed/NCBI
|
25
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Huang TH, Wu F, Loeb GB, Hsu R,
Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, et
al: Up-regulation of miR-21 by HER2/neu signaling promotes cell
invasion. J Biol Chem. 284:18515–18524. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Qi L, Bart J, Tan LP, Platteel I, Sluis T,
Huitema S, Harms G, Fu L, Hollema H and Berg A: Expression of
miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia
of the breast in relation to ductal carcinoma in situ and invasive
carcinoma. BMC Cancer. 9:1632009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Li T, Li D, Sha J, Sun P and Huang Y:
MicroRNA-21 directly targets MARCKS and promotes apoptosis
resistance and invasion in prostate cancer cells. Biochem Biophys
Res Commun. 383:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z,
Fan Y, Chen X and Wu C: Re-expression of miR-21 contributes to
migration and invasion by inducing epithelial-mesenchymal
transition consistent with cancer stem cell characteristics in
MCF-7 cells. Mol Cell Biochem. 363:427–436. 2012. View Article : Google Scholar
|
32
|
Chun HK, Jung KU, Choi YL, Hong HK, Kim
SH, Yun SH, Kim HC, Lee WY and Cho YB: Low expression of
transforming growth factor beta-1 in cancer tissue predicts a poor
prognosis for patients with stage III rectal cancers. Oncology.
86:159–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Li Q, Zhang D, Wang Y, Sun P, Hou X,
Larner J, Xiong W and Mi J: miR-21/Smad 7 signaling determines
TGF-β1-induced CAF formation. Sci Rep. 3:20382013.
|
34
|
Wang JY, Gao YB, Zhang N, Zou DW, Wang P,
Zhu ZY, Li JY, Zhou SN, Wang SC, Wang YY, et al: miR-21
overexpression enhances TGF-β1-induced epithelial-to-mesenchymal
transition by target smad7 and aggravates renal damage in diabetic
nephropathy. Mol Cell Endocrinol. 392:163–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Petrović N, Mandušić V, Dimitrijević B,
Roganović J, Lukić S, Todorović L and Stanojević B: Higher miR-21
expression in invasive breast carcinomas is associated with
positive estrogen and progesterone receptor status in patients from
Serbia. Med Oncol. 31:9772014. View Article : Google Scholar
|
36
|
Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N,
Zhu Z, Mo Z, Wu C and Chen X: MiR-21 regulates
epithelial-mesenchymal transition phenotype and hypoxia-inducible
factor-1α expression in third-sphere forming breast cancer stem
cell-like cells. Cancer Sci. 103:1058–1064. 2012. View Article : Google Scholar : PubMed/NCBI
|
37
|
Marino AL, Evangelista AF, Vieira RA,
Macedo T, Kerr LM, Abrahão-Machado LF, Longatto-Filho A, Silveira
HC and Marques MM: MicroRNA expression as risk biomarker of breast
cancer metastasis: A pilot retrospective case-cohort study. BMC
Cancer. 14:7392014. View Article : Google Scholar : PubMed/NCBI
|
38
|
Petrović N, Mandušić V, Stanojević B,
Lukić S, Todorović L, Roganović J and Dimitrijević B: The
difference in miR-21 expression levels between invasive and
non-invasive breast cancers emphasizes its role in breast cancer
invasion. Med Oncol. 31:8672014. View Article : Google Scholar
|
39
|
Chen J and Wang X: MicroRNA-21 in breast
cancer: Diagnostic and prognostic potential. Clin Transl Oncol.
16:225–233. 2014. View Article : Google Scholar
|
40
|
Azuma H, Ehata S, Miyazaki H, Watabe T,
Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, et
al: Effect of Smad7 expression on metastasis of mouse mammary
carcinoma JygMC(A) cells. J Natl Cancer Inst. 97:1734–1746. 2005.
View Article : Google Scholar : PubMed/NCBI
|